Scientists dive deep into the roots of a mysterious lung disease

NCT ID NCT00001465

Recruiting now Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the proteins and genes responsible for lung destruction, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new treatments for LAM by identifying key proteins and genes involved in lung destruction.
What could go wrong: This is an observational study, not a treatment trial. It may not directly lead to therapies, and results may take years to translate into clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung disorder lymphangioleiomyomatosis pneumothorax tuberous sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG DISEASE LYMPHANGIOLEIOMYOMATOSIS PNEUMOTHORAX TUBEROUS SCLEROSIS

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.